Protected handling of plasmid DNA (pDNA)

Reliable fluid management and cold chain stability for pDNA used in gene therapy, viral vector, and mRNA production.

Top-down view of an open RoSS.KSET containing a small single-use bag, with a hand holding it.

Why Single Use Support in pDNA manufacturing?

High production costs?

Product loss and process variability across purification, fluid handling steps, and cryopreservation can negatively impact overall yield and process efficiency.

Green icon of two single-use bags with even distribution on a transparent background demonstrating homogeneity

Efficient with process flexibility

Significant improvements in efficiency can be achieved by optimizing specific cost drivers, such as batch-to-batch variability, inaccuracies, and product loss during purification, liquid transfer, and cryopreservation.

Transferring viscous pDNA?

Especially after cell lysis, the viscosity of plasmid DNA represents a challenge in ensuring uniformity during liquid transfer and aliquotation processes.

Green icon of a droplet and a protective shield on a transparent background demonstrating aseptic decoupling

Consistent, controlled fluid path

In order to aliquot small volumes of pDNA, manufacturers are advised
to ensure bag-to-bag consistency throughout small-sized single-use bags, employing homogenization and automated aliquotation.

CQAs affected by freezing?

Maintaining plasmid integrity during freezing, storage, and shipping is critical to preserving critical quality attributes (CQA) of the pDNA and minimizing the risk of degradation and batch-to-batch variability.

Green icon of a thermometer on a transparent background demonstrating temperature control

Controlled freezing of pDNA

By implementing controlled freeze-thaw processes and a scalable freeze-to-store workflow, manufacturers can significantly improve product quality to ensure the delivery of more effective therapies to patients.

Test tubes in a well plate with a blurred blue background.

Plasmid DNA (pDNA) manufacturing

Using E.coli fermentation, Plasmid DNA is produced in large bioreactors to generate enough biomass to inoculate a larger fermenter, followed by clarification, filtration steps in downstream bioprocessing.

The manufacturing process is typically slow, expensive, has limited capacity, and is vulnerable to batch failure. Flexible and scalable platforms supporting a GMP-compliant plasmid DNA manufacturing improve commercial production.

An operator in front of controlled rate freezer RoSS.pFTU Mid-Scale by Single Use Support after cell freezing with dmso.

pDNA production for manufacturing mRNA and viral vectors

Plasmid DNA (pDNA) is used for a wide range of applications in research, preclinical and clinical studies, for example:

  • As a starting material for the production of mRNA.
  • As a payload for LNP non-viral vectors
  • For producing viral vectors, such as AAVs and lentiviral vectors.

For all areas of application it is important to consider controlled and reliable processes for aliquotation & filtration, freeze & thaw, ultra cold storage and shipment between the major production steps of pDNA like fermentation, cell harvest, and clarification.

Preview of an app note about filling and freezing of RNA therapeutics

DOWNLOAD APP NOTE

The Chilled Future of RNA Therapeutics Filling & Freezing Applications - App Note

This application note explores scalable, GMP-compatible solutions for the sterile filling and cryopreservation of mRNA, pDNA, and viral vectors. It presents modular technologies that ensure temperature control, minimize product loss, and support high-accuracy aliquotation - paving the way for efficient commercialization of RNA-based therapeutics.

  • Optimizing pDNA production using advanced single-use technologies

    The field of plasmid DNA (pDNA) is witnessing remarkable innovations and advances. As the demand for therapeutic DNA continues to surge, so does the need for efficient, scalable, and safe manufacturing processes. In response to this demand, the integration of single-use technologies (SUTs) has emerged as a transformative force, developing further stages of pDNA production. In this comprehensive guide, we delve into the exciting field of pDNA manufacturing, with a focus on the groundbreaking impact of single-use technologies. From improving the filling process to optimized freezing, storage, and shipping of the final product – the integration of single-use technologies has paved the way for streamlined operations, reduced contamination risks, and increased overall efficiency. Single-use technologies in pDNA manufacturing Improving pDNA manufacturing steps The process of transforming raw materials into the final therapeutic product in biopharmaceutical production is a complex undertaking for pDNA manufacturing companies. Several key manufacturing steps are essential in guaranteeing the quality, purity, and potency of plasmid DNA. However, the current methods of pDNA manufacturing often present challenges such as contamination risks, time-consuming processes, and limitations in scalability. Furthermore, manufacturing requirements can change quickly, which requires a high level of process versatility. The incorporation of single-use technologies is a groundbreaking approach that is reshaping pDNA manufacturing. The inclusion of SUTs at different stages of manufacturing has initiated an era of enhanced efficiency, accuracy, and adaptability. In the following chapters, we will explore the developments that are transforming pDNA production, streamlining the entire process to enhance efficiency, cut costs, and improve quality – one stage at a time. Homogenization of pDNA Homogenization is a critical step in the plasmid DNA (pDNA) manufacturing process, aimed at ensuring uniformity and consistent dispensing of plasmid DNA into single-use bioprocess containers. With the integration of advanced single-use technologies, this step is experiencing a transformative enhancement. Homogenization traditionally involves mechanical processes that require significant manual intervention. The process can therefore be time-consuming and, above all, result in aliquot-to-aliquot deviations. Automated platforms based on single-use technologies gently agitate and mix pDNA to ensure consistent distribution. In fact, automated solutions facilitate process standardization and thereby reduces the risk of inconsistencies within the solution. Filling & Filtration of pDNA with single-use technologies The implementation of single-use technologies has substantially enhanced the filling process of plasmid DNA into storage containers. SUTs utilize customized single-use bags that are designed to maintain sterility and prevent contamination risks, which obviates the necessity for extensive cleaning. The employment of automation further boosts the accuracy and productivity of pDNA filling. Automated fluid management systems utilizing single-use technologies are controlled platforms for the standardized filling & filtration of pDNA. This leads to increased accuracy while reducing potential for human errors. The systems are capable of accommodating varying batch sizes without compromising quality, making them scalable. Moreover, sterile bags and automated systems contribute to product integrity, meeting regulatory as well as cGMP standards while ensuring patient safety. Accurate dosing of pDNA is essential for maintaining product quality and meeting regulatory requirements. SUTs streamline the aliquotation process, providing automated systems that precisely divide large pDNA solutions into smaller, uniform aliquots. This automation not only enhances accuracy but also minimizes the risk of contamination during aliquotation, contributing to overall process efficiency. The integration of dedicated fluid management solutions by Single Use Support brings several advantages: Automation reduces manual labor, minimizing the potential for human error and ensures reproducibility. Additionally, the pre-sterilized components reduce cross-contamination risks, enhancing the integrity of the pDNA product. The scalable nature of Single Use Support’s fluid management platform enables manufacturers to adapt to varying production scales without compromising quality. Freezing plasmid DNA with SUT Freezing plasmid DNA is crucial for its long-term stability and functionality. However, the conventional freezing process can introduce challenges such as cryoconcentration and temperature inconsistencies that might compromise pDNA integrity. Traditionally, pDNA freezing involves placing samples in vials or other containers and subjecting them to cryogenic freezing with little control over the freezing process. This can lead to inhomogeneous freezing rates, resulting in the formation of damaging ice crystals that may disrupt the DNA structure. Additionally, temperature fluctuations and an extended phase transition during storage can further impact pDNA stability, requiring additional stability testing and posing risks to product integrity. However, with innovative plate-based freezers that allow full control over the freezing rates, the process can be tailored to the exact need of plasmid DNA. Covered in single-use bag protection, the single-use bags containing pDNA can be frozen at low freezing rates (usually down to -80 °C), allowing for more even freezing results and better overall product quality. Plasmid DNA storage and shipping – enhancements with single-use technologies Storing and shipping plasmid DNA (pDNA) requires dedicated process solutions, making sure that cold chain integrity is granted. One primary challenge lies in temperature variations, which can compromise pDNA quality. Traditional storage methods often struggle to uphold the low temperatures with best air temperature uniformity required for preservation. Single-use cold chain shipping containers can be deployed to maintain temperature consistency, preventing deviations that can harm pDNA samples. Maximizing space efficiency in pDNA storage and shipping is a critical hurdle. Traditional walk-in freezers can be bulky and space-consuming, while lab freezers are too small for larger amounts of pDNA. The ultra-cold storage freezer RoSS.ULTF fills this gap, providing air temperature uniformity and stackability. The modular setup optimizes space utilization and frees up valuable laboratory area. ULT freezers must not only be space-efficient themselves, but also have to provide high storage density. Therefore, Single Use Support offers compatible protection for every primary packaging, including single-use bags in all sizes – compact and stackable. Allowing for ULT freezers to be filled efficiently, they fit various storage needs and are scalable to accommodate different batch sizes and requirements. Start Pharma 4.0 – read more Advanced pDNA production with Single Use Support In the fast-paced realm of biopharmaceutical production, Single Use Support has established itself as a specialist in single-use technologies. These cutting-edge solutions are carefully crafted for plasmid DNA manufacture, optimizing the effectiveness and excellence of the entire pDNA production process. By seamlessly integrating Single Use Support's products, pDNA production can be improved. Plasmid DNA can be filled into IRIS single-use bioprocess containers, which can be protected by RoSS.KSET. Fluid management can be streamlined with automated solutions for homogenous filling, reducing the need for manual intervention. Single Use Support's expertise extends to cold chain logistics: With a plate-based freeze/thaw platform, fast and controlled freezing rates can be achieved that help maintain the quality of pDNA. Subsequently, the frozen substances are ready for storage in RoSS.ULTF – Single Use Support ULT freezer – or transport in RoSS.SHIP. This revolutionary cold chain shipping container is not only extremely space efficient, but – most importantly – guarantees temperature integrity during transit. It reduces temperature variations and maintains pDNA quality in difficult shipping conditions. Aligned with the high demands in drug development and drug delivery, single-use technologies bring a variety of advantages in the production of plasmid DNA: Enhanced process efficiency: Streamlined processes and reduced manual interventions lead to increased operational efficiency. Maximized process safety: Closed single-use systems minimize the risk of contamination, ensuring product purity. Flexibility: Modular designs allow easy adaptation to varying production scales and product requirements. Cost savings: Elimination of complex cleaning and validation processes results in significant cost reduction. Reduced time-to-market: Faster setup and reduced validation cycles contribute to quicker product development and market entry. Seamless adaptability: Single Use Support's solutions seamlessly integrate storage, freezing, and shipping processes. Reduced environmental impact: Reduced water usage, energy consumption, and waste generation help make pDNA production more sustainable.   Filling & freezing of small volumes

    READ MORE
  • Plasmid DNA – 7 facts about pDNA

    Plasmid DNA stands as a fascinating topic in the field of molecular biology. This double-stranded nucleic acid molecule is known for its versatility as a genetic vehicle and holds numerous intriguing characteristics. From autonomous replication to its significance in pDNA manufacturing for biopharmaceutical processes, researchers and biotechnologists continue to be intrigued by plasmid DNA. In this article, we delve into pDNA characteristics and functions, uncovering the profound impact of these DNA fragments within the fascinating tapestry of life. pDNA – read more Fact 1: Plasmids – not the sole DNA in bacteria In bacterial genetics, plasmid DNA is recognized as a key factor, however, it shares the stage with another crucial player: chromosomal DNA. Bacterial cells, such as E. coli, possess a genomic landscape comprising both plasmid and chromosomal DNA. These two genetic components possess unique characteristics and roles that intricately shape bacterial life.[[1]] Chromosomal DNA serves as the cornerstone of a bacterium's genetic makeup. It contains the core genetic information essential for cellular functions, growth, and reproduction. The chromosomal DNA in bacterial cells is linear and organized into a single, continuous molecule, encompassing a broad array of genes responsible for a bacterium's physiological traits. In contrast, bacterial plasmid DNA is an auxiliary genetic element within bacterial cells. Unlike chromosomal DNA, plasmids are small, circular DNA molecules that exist independently from the chromosomal genome. They often carry genes that confer specific advantageous traits, such as the ability to metabolize unique substances. Plasmids can be shared among bacterial cells through processes like conjugation, enabling the spread of beneficial traits within a bacterial community.[[1]] What is a plasmid? Fact 2: Plasmids were discovered 80 years ago The 20th century witnessed a watershed moment in the field of genetics with the discovery of plasmids. This revelation unveiled a previously unseen dimension of bacterial genetics, revolutionizing our comprehension of genetic diversity and information transfer within microorganisms. The story of plasmids' discovery is interwoven with groundbreaking experiments that unraveled their existence. It wasn't until the mid-20th century that researchers began to decipher the intricate genetic architecture of bacterial cells. The pioneering work of scientists like Joshua Lederberg illuminated the presence of extrachromosomal elements, distinct from the primary chromosomal DNA. Plasmids, as these newfound genetic entities came to be known, provided opportunities for investigating the adaptable realm of horizontal gene transfer. This pertains to the capacity for bacteria to exchange genetic material beyond the confines of reproduction. This discovery upended the traditional view of genetics as solely a vertical process, where genes are passed from parent to offspring. The significance of plasmid discovery transcended the laboratory. It laid a foundation for genetic engineering, enabling scientists to manipulate and engineer these small, circular pieces of DNA. This pivotal breakthrough spurred advancements in biotechnology, medicine, and agriculture. Notably, the emergence of recombinant DNA technology and its application in gene therapy is intensely linked to the revelation of plasmids. Fact 3: Plasmid DNA replicates independently Plasmid DNA exhibits a unique ability: autonomous replication. Unlike chromosomal DNA, plasmid DNA can self-duplicate due to its distinct origin of replication. This self-replicating nature grants plasmids autonomy in propagating their genetic information, setting them apart in the realm of cellular replication.[[2]] Fact 4: There are 5 types of plasmid DNA with distinct functions The world of plasmid DNA contains a variety of diversity, with specific types shaping the genetic landscape of bacterial communities. These five plasmid categories possess unique attributes that determine the functions of pDNA. Resistance (R) Plasmids: Among the most renowned, R plasmids bear genes encoding resistance to antibiotics. This genetic armor equips bacteria with the power to withstand antimicrobial agents, presenting challenges in clinical settings. Fertility (F) Plasmids: F plasmids coordinate bacterial conjugation, a process similar to mating. By aiding the gene transfer between bacterial cells, they promote genetic diversity and swift adaptation to changing environments. Col Plasmids: Often observed in Escherichia coli, plasmids in this bacterium secrete colicins – toxins that specifically target closely related bacteria. This advantageous trait supports niche establishment and resource acquisition. Virulence Plasmids: Crucial to pathogenic bacteria, virulence plasmids contain genes that enable these microbes to colonize hosts and cause disease. This indicates the complex interplay between bacteria and their host organisms. Degradative Plasmids: Degradative plasmids carry genes that enable bacteria to metabolize unique substances found in their environment, allowing them to utilize a variety of energy sources. This showcases the remarkable adaptability of bacterial communities. Fact 5: Plasmid DNA can be recombinantly produced Plasmid DNA's flexibility extends to recombinant production through sophisticated genetic engineering techniques. Desired DNA sequences of interest can be cloned into plasmids utilizing restriction enzymes and PCR amplification, allowing for precise customization. Plasmids can be transformed as versatile tools by encoding specific traits required for DNA vaccines. This manipulation takes place in vitro, outside of living organisms, enabling controlled experimentation. Emerging technologies, such as CRISPR, continue to advance plasmid modification, while conjugation facilitates plasmid transfer between bacteria. This purposeful utilization of plasmids in recombinant production highlights their fundamental role in modern genetic research, biotechnology and medicine. Read more: Plasmid DNA manufacturing companies – market overview Fact 6: Plasmids can function as vectors The function of plasmids goes beyond serving as vectors in bacterial cells, aiding in the modification and transfer of genetic information. This skill is used in diverse areas, including genetic research and medical advances like mRNA (messenger RNA) production. Plasmids can be modified to contain foreign DNA segments – genes of interest –, that can then be replicated within the host cells. This technique, also known as cloning, enables scientists to harness the power of bacterial replication machinery to generate multiple copies of a particular DNA sequence. The inserted gene can also be equipped with regulatory elements, such as promoters, thereby guaranteeing regulated gene expression. In the laboratory, plasmids serve as essential tools for studying gene function and regulation. Researchers can introduce plasmid constructs into cells and observe their effects. Moreover, plasmids find relevance in vivo, demonstrating their potential to influence gene expression and cell behavior within living organisms. Plasmids shine brightly in the field of gene therapy, as they allow for the delivery of therapeutic genes into target cells, offering potential cures for genetic disorders or providing novel treatments for various diseases. Plasmids serve as vehicles for genetic healing through the process of transfection, which involves introducing foreign genetic material into cells. Fact 7: pDNA manufacturing comes with complexities The realm of plasmid DNA (pDNA) manufacturing presents significant challenges for pharmaceutical companies aiming to harness its potential. While pDNA holds immense promise for gene therapy, DNA vaccines, and other applications, its production involves challenges. Purification methods, like electrophoresis and alkaline lysis, require careful calibration to ensure the yield of high-quality, supercoiled pDNA. The specter of endotoxin contamination adds another layer of complexity, necessitating stringent purification processes. And scaling up production from lab-scale to commercial quantities demands meticulous optimization. Successfully navigating these hurdles demands a comprehensive understanding of plasmid preparation, manufacturing techniques, and regulatory compliance, ultimately dictating the success of pDNA-based biopharmaceutical endeavors. Single Use Support is ready to face these challenges together with biopharmaceutical companies. With a dedicated product line-up for pDNA manufacturing in the field of fluid and cold chain management, the production of DNA plasmids can increase in safety, efficiency and scalability. Based on optimization of pDNA manufacturing with single-use technologies, processing steps like fluid management (including aliquotation and homogenization) can be streamlined, eliminating the need for cost- and resource-intensive cleaning processes at the manufacturing site. This also reduces water and energy consumption, thus the environmental impact. Furthermore, controlled-rate freeze-thaw platforms open doors to a customized freezing process of different volumes of pDNA. While single-use bioprocess containers are covered and protected by robust secondary packagings, both plate-based freeze-thaw platforms and liquid-nitrogen-based cryogenic freezers enable cooling of pDNA for safe cryopreservation. The high level of automatization that comes with Single Use Support’s platform systems minimize the need for human intervention and therefore the risk of human error, while operating costs can be lowered. This is how Single Use Support provides innovative solutions that help pDNA manufacturers in bringing their processes to the next level. Single-use technologies in Plasmid DNA manufacturing References https://www.genome.gov/genetics-glossary/Plasmid , Published 2023 Plasmid,  https://www.whatisbiotechnology.org/index.php/science/summary/plasmid/ , Published

    Read more
  • Plasmid DNA manufacturing companies – market overview

    On the biopharmaceutical market, plasmid DNA manufacturing companies have become essential players, as pDNA has enabled significant advancements in biotechnology. Whether it’s gene therapy, the development of DNA vaccines, or the production of cell therapies, recombinant antibody therapies and other advanced therapies, plasmid DNA is the starting material for many products that have fundamentally transformed the healthcare sector. The demand for specialized plasmid DNA manufacturing companies in the pharma industry is reasonably high due to the complexity and intricacies of the production process. The density of biotech companies working with pDNA illustrates the enormous market size – and the competition in the attempt to offer the most appealing services. In this article, we will give an overview of the pDNA manufacturing market – not only taking a look at the dry figures, but also highlighting the services that are offered by important plasmid DNA manufacturing companies. Single-use technologies in pDNA manufacturing pDNA market overview – continuous growth The growth trajectory of the pDNA market is considerable: While there has already been an increase in the global market size from USD 306.40 million in 2020 to USD 446.13 million only two years later, this development is predicted to continue. One of the most important segments is the cell and gene sector, with a market share of almost 60 % in 2022.[[1]] By 2030, the plasmid DNA manufacturing market size is expected to amount to more than USD 2 billion, with a CAGR of 21.7 % in the forecast period. This growth can be traced back to factors like an increased interest in DNA-based vaccines and gene therapies, but also to the high interest in pDNA for various other applications, along with the general growth of the biopharmaceutical market.[[1]] Individual steps involved in the manufacturing process of biopharmaceutical products, such as viral vector manufacturing (e.g. AAV production), non-viral vector production, RNA synthesis or fermentation, require specific knowledge and compliance to regulatory standards. Therefore, many biopharma companies rely on CDMOs: organizations and institutes that specialize in specific tasks, possessing the requisite knowledge, resources and capabilities as in the case of pDNA manufacturing companies.[[1]] pDNA manufacturing services pDNA manufacturing companies, often at the forefront of biopharmaceutical innovations, offer services that extend beyond mere manufacturing. From research grade plasmid DNA production for pre-clinical trials to GMP grade plasmid DNA production for large-scale applications, serving the entire range of scientific exploration. pDNA production for pre-clinical trials Navigating the journey from scientific hypotheses to clinical breakthroughs includes an essential stopover of pre-clinical trials. Here, production of plasmid DNA (pDNA) takes on a distinctive role, characterized by smaller volumes and precise parameters. The services offered by pDNA manufacturing companies play a pivotal role in ensuring the quality and integrity of the genetic material crucial for these preliminary tests. Plasmid DNA production for clinical applications As scientific endeavors delve into clinical trials, there is a growing need for greater quantities of high-quality pDNA surges. Manufacturing companies are stepping up their game, offering expertise that goes beyond the confines of the laboratory and ensures the smooth transition of research-grade pDNA into clinical-grade material. The success of this complex process depends heavily on the precision of such manufacturing services, which must adhere to stringent regulations. GMP plasmid DNA manufacturing for large-scale applications Scaling up production to meet industry demands presents a unique set of challenges. Firstly, larger facilities are required, designed to facilitate efficient processes and provided with equipment capable of processing grater quantities. Furthermore, bulk production of pDNA necessitates adherence to current Good Manufacturing Practices (cGMP) as well as regulatory standards (e.g. issued by the FDA), assuring safety and quality. As pDNA manufacturing companies take on the responsibility of large-scale production, their role becomes paramount in shaping the trajectory of advanced therapies and healthcare. However, meticulous quality control as well as an increased focus on cost and resource efficiency are even more important. Plasmid DNA manufacturing companies – big players in the market The pDNA manufacturing market is influenced by various biopharma companies of different sizes from around the world. These companies operate in countries such as the USA, India and Japan, France, Germany and many other locations across Europe, Africa, America and the Asia Pacific region. A recent report on the pDNA market lists important companies that are concerned with pDNA manufacturing – here are some of them:[[2]] VGXI, Inc. Cobra Biologics & Pharmaceutical Services (now part of Charles River) JAFRAL Ltd. Aldevron [[2]] Biggest challenges and opportunities for pDNA manufacturing companies pDNA manufacturing companies face significant challenges that hinder growth. These hurdles, while demanding, offer a roadmap for companies to chart their paths to success. Among the most pressing challenges is production scale-up, a crucial endeavor for meeting market demands. Bringing the production level from lab to bulk scale raises technological and logistic considerations: Especially the cultivation of healthy cells in higher quantities is challenging. [[4]] The imperative to adhere to Current Good Manufacturing Practices (cGMP) poses further intricate challenges. However, this ensures that every facet of the manufacturing process aligns with stringent regulatory standards, resulting in safe and effective products. Another significant challenge centers around process efficiency and cost-effectiveness. As the industry advances, finding methods to streamline manufacturing processes without compromising quality remains paramount, especially around the linking points of existing and scaled-up solutions, which also have to be GMP-compatible and efficient. In this pursuit, companies must deal with the complexities of homogenization, aliquotation, and freeze/thaw cycles, all of which affect the final product's integrity and functionality. Moreover, the constant evolution of scientific understanding necessitates a continuous commitment to research and development, further straining resources. However, within these challenges lies a landscape of opportunities. Innovations based on single-use technologies that address these hurdles catalyze growth and steer the course of the pDNA market, with automated solutions becoming a frequent choice in the biopharmaceutical sector. [[3]] Optimizing pDNA production with SUT Supporting pDNA manufacturers with advanced technologies In their quest to maximize the potential of plasmid DNA, pDNA manufacturers require cutting-edge technologies that balance the fragility of genetic material with the imperatives of affordability and productivity. This is particularly vital given the rapidly evolving landscape of pDNA manufacturing. Therefore, Single Use Support has developed a range of machines, single-use assemblies and bioprocess containers to streamline the pDNA manufacturing process at every scale. As part of fully scalable platforms, solutions such as Single Use Support’s fluid management system or various freezing devices are equally applicable to lab and bulk scale applications. Furthermore, dedicated aliquotation and homogenization ensure the efficient distribution of valuable biological materials while meeting cGMP relevent quality standards and regulatory requirements. In addition, the systems feature a high degree of automation, which minimizes the need for human intervention, thereby reducing the risk of human error and staffing requirements. Water and energy savings can be achieved through Single Use Support’s single-use systems, which require less laborious cleaning and sterilization processes compared to traditional solutions. Additionally, proper waste management can enhance sustainability of single-use technologies more effectively than using traditional solutions. From combating infectious diseases or various cancer types with novel immunotherapies to vaccine development: pDNA is an extremely versatile genetic fragment and a cornerstone in modern biopharmaceutical processes. And Single Use Support is proud to aid pDNA manufacturers in pushing the latest developments even further. [[4]] Single-use technologies in pDNA manufacturing References Plasmid DNA Manufacturing Market (By Product: Viral Vectors, Plasmid DNA, Non-Viral, Electroporation, Lipid/Polymer, Nanoparticles, and Others; By Application: Gene Therapy, DNA Vaccines, Immunotherapy, Others; By Disease: Infectious Disease, Genetic Disorder, and Cancer) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022 - 2030, https://www.precedenceresearch.com/plasmid-dna-manufacturing-market, Published Plasmid DNA Manufacturing Market (By Product: Viral Vectors, Plasmid DNA, Non-Viral, Electroporation, Lipid/Polymer, Nanoparticles, and Others; By Application: Gene Therapy, DNA Vaccines, Immunotherapy, Others; By Disease: Infectious Disease, Genetic Disorder, and Cancer) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022 - 2030, https://www.precedenceresearch.com/plasmid-dna-manufacturing-market, Published Plasmid DNA Manufacturing Market (By Product: Viral Vectors, Plasmid DNA, Non-Viral, Electroporation, Lipid/Polymer, Nanoparticles, and Others; By Application: Gene Therapy, DNA Vaccines, Immunotherapy, Others; By Disease: Infectious Disease, Genetic Disorder, and Cancer) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022 - 2030, https://www.precedenceresearch.com/plasmid-dna-manufacturing-market, Published Advancing sustainability in the pharmaceutical industry, https://cen.acs.org/acs-news/comment/Advancing-sustainability-pharmaceutical-industry/98/i17, Published 2020

    READ MORE

Talk to an expert